|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||8.00 - 8.00|
|52-week range||7.00 - 11.95|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Nov 2017|
|1y target est||N/A|
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
TEL AVIV, Israel, September 08, 2022--Teva Pharmaceutical Industries Ltd. today announces the results of two studies1,2 presented at the Migraine Trust International Symposium (MTIS) in London, UK, which demonstrate the efficacy of AJOVY▼ (fremanezumab) in migraine patients who also experience depression or anxiety. AJOVY▼ (fremanezumab) is indicated for the prevention of migraine in adults with at least 4 migraine days per month.8